These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25598933)

  • 21. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 22. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
    Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
    Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
    Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
    Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
    Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
    Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
    Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
    Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
    Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
    Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
    Tong M; Jin YY; Li G; Liu SM; Ji CD
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
    Izmirli M; Arikan B; Bayazit Y; Alptekin D
    Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
    Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
    Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
    Li J; Coates RJ; Gwinn M; Khoury MJ
    Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression.
    Akalu A; Dlmajian DA; Highshaw RA; Nichols PW; Reichardt JK
    J Urol; 1999 Apr; 161(4):1355-8. PubMed ID: 10081907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between
    Sun L; Zhou M; Liu T
    Pharmazie; 2019 Feb; 74(2):125-128. PubMed ID: 30782264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men.
    Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Liao C; Wang X; Chan FW; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
    Clin Chem; 2010 Nov; 56(11):1742-9. PubMed ID: 20855474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between KL polymorphism and prostate cancer risk in Korean patients.
    Kim HJ; Lee J; Lee SY; Cheong HS; Kye YS; Kim W; Byun SS; Myung SC
    Mol Biol Rep; 2014 Nov; 41(11):7595-606. PubMed ID: 25120167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
    Li Q; Zhu Y; He J; Wang M; Zhu M; Shi T; Qiu L; Ye D; Wei Q
    Mol Biol Rep; 2013 May; 40(5):3597-608. PubMed ID: 23277398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications.
    Fang C; Guo ZQ; Chen XY; Liu TZ; Zeng XT; Wang XH
    Medicine (Baltimore); 2017 May; 96(19):e6791. PubMed ID: 28489754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
    Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE; Reichardt JK; Nguyen H; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.